DrugPatentWatch Database Preview
Rempex Pharms Company Profile
What is the competitive landscape for REMPEX PHARMS, and what generic alternatives to REMPEX PHARMS drugs are available?
REMPEX PHARMS has two approved drugs.
There are six US patents protecting REMPEX PHARMS drugs.
There are fifty-three patent family members on REMPEX PHARMS drugs in twenty-three countries and eight supplementary protection certificates in four countries.
Summary for Rempex Pharms
| International Patents: | 53 |
| US Patents: | 6 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Rempex Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rempex Pharms | MINOCIN | minocycline hydrochloride | INJECTABLE;INJECTION | 050444-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | 9,278,105 | Start Trial | Start Trial | ||||
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | 10,183,034 | Start Trial | Start Trial | ||||
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | 8,680,136 | Start Trial | Y | Y | Start Trial | ||
| Rempex Pharms | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | 9,694,025 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Rempex Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2013529201 | Start Trial |
| Japan | 2016145253 | Start Trial |
| Poland | 2603514 | Start Trial |
| European Patent Office | 2568987 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Rempex Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2603514 | 2019C/514 | Belgium | Start Trial | PRODUCT NAME: UNE COMBINAISON DE VABORBACTAM, ET / OU D'UN DE SES SELS ET / OU HYDRATES, ET DU MEROPENEME, ET / OU DE SON SEL ET / OU DE SON HYDRATE, EN PARTICULIER DU MEROPENEME TRIHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/18/1334 20181122 |
| 2603514 | 300977 | Netherlands | Start Trial | PRODUCT NAME: EEN COMBINATIE VAN VABORBACTAM, EN/OF EEN ZOUT EN/OF EEN HYDRAAT DAARVAN, EN MEROPENEM, EN/OF EEN ZOUT EN/OF EEN HYDRAAT DAARVAN, IN HET BIJZONDER MEROPENEM TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/18/1334 20181122 |
| 2603514 | CA 2019 00016 | Denmark | Start Trial | PRODUCT NAME: VABORBACTAM, OG/ELLER ET SALT OG/ELLER HYDRAT HERAF; REG. NO/DATE: EU/1/18/1334 20181122 |
| 2603514 | 122019000026 | Germany | Start Trial | PRODUCT NAME: VABORBACTAM, UND/ODER EIN SALZ UND/ODER EIN HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/18/1334 20181120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
